Evidence map›Paper›PMID 33119664›Full record

Trial reportPloS one2020

Neutrophil extracellular trap components and myocardial recovery in post-ischemic acute heart failure.

Miriam Sjåstad Langseth, Geir Øystein Andersen, Trygve Husebye, Harald Arnesen, Manuela Zucknick, Svein Solheim, Jan Eritsland, Ingebjørg Seljeflot, Trine Baur Opstad, Ragnhild Helseth

Registry-linked trialOpen access · goldAbstract readClinical TrialObservational Study
In one paragraph

Trial report in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00324766 (Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00324766 phase4completednot on this map

Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.

TypeinterventionalSponsorOslo University HospitalRan2006 to 2012Enrolled61ConditionsMyocardial Infarction, Heart Failure, Cardiogenic ShockArmslevosimendan, placebo,
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Miriam Sjåstad LangsethCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.ORCID 0000-0002-4880-3019
Geir Øystein AndersenCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Trygve HusebyeDepartment of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
Harald ArnesenCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Manuela ZucknickOslo Centre for Biostatistics and Epidemiology, Institute for Basic Medical Sciences, University of Oslo, Oslo, Norway.
Svein SolheimCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Jan EritslandDepartment of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
Ingebjørg SeljeflotCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Trine Baur OpstadCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Ragnhild HelsethCenter for Clinical Heart Research, Oslo University Hospital Ullevål, Oslo, Norway.
Oslo University Hospital · NOUniversity of Oslo · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe role of neutrophil extracellular traps (NETs) in acute heart failure is unknown. We recently showed that interleukin 8, a putative NETs stimulator, was associated with myocardial recovery in acute heart failure complicating ST-elevation myocardial infarction (STEMI). In this exploratory post-hoc study, we aimed to investigate the role of NETs components in relation to myocardial function and interleukin 8 in STEMI patients with symptomatic acute heart failure.

methodsIn 61 STEMI patients developing acute heart failure within 48 hours of successful revascularization, wall motion score index (WMSI), global longitudinal strain (GLS) and left ventricular ejection fraction (LVEF) were assessed by echocardiography at baseline and on day 5. Blood drawn at baseline and days 1, 2 and 5 was used to quantify double-stranded DNA (dsDNA), myeloperoxidase-DNA complexes (MPO-DNA) and citrullinated histone 3 (CitH3). The area under the curve (AUC) of each NETs marker and interleukin 8 was approximated for the first 5 days.

resultsdsDNAAUC and MPO-DNAAUC correlated significantly with change in WMSI from baseline to day 5 (rs = 0.28 for both, p≤0.05), whereas NETs AUCs did not correlate with changes in GLS and LVEF. dsDNAAUC was significantly correlated with interleukin 8AUC (r = 0.40, p = 0.003). However, mixed model regression could not identify a significant effect of the NETs components on myocardial function parameters.

conclusionsIn this cohort with acute heart failure complicating STEMI, NETs components were partly correlated with myocardial function and interleukin 8 levels, yet no causal relationship between NETs components and myocardial recovery could be established. CLINICAL

trial registrationClinicalTrials.gov, identifier: NCT00324766.

Indexed as

Recovery of FunctionAdultAgedAged, 80 and overDNAEchocardiographyExtracellular TrapsFemaleHeart FailureHistonesHumansInterleukin-8MaleMiddle AgedMyocardiumPeroxidaseCXCL8 protein, humanDNAHistonesInterleukin-8MPO protein, humanPeroxidase

Identifiers

PMID33119664
PMCPMC7595325
OpenAlexW3096120286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.